Table 4
From the following article
Chinese health biotech and the billion-patient market
Sarah E Frew, Stephen M Sammut, Alysha F Shore, Joshua K Ramjist, Sara Al-Bader, Rahim Rezaie, Abdallah S Daar & Peter A Singer
Nature Biotechnology 26, 37 - 53 (2008)
doi:10.1038/nbt0108-37
Table 4. Subsidiaries, joint ventures and affiliated institutes for companies interviewed
| Company name | Subsidiary, joint ventures or affiliate |
|---|---|
| CapitalBio | Outlicensed technology to AVIVA Biosciences (San Diego) for development and marketing of on-chip patch-clamp technologies for ion-channel studies in drug discovery research. Small-molecule candidates outlicensed to Chipscreen Biosciences (Shenzhen, China) for use in, for example, type II diabetes and cancer. Wholly owned subsidiaries are CapitalBio International (San Diego) and CapitalBio Hong Kong (Hong Kong). Affiliated with National Engineering Research Centre for Beijing Biochip Technology (Beijing). |
| HD Biosciences | Shares facilities and human resources with Beijing Genomics Institute (Beijing), which is also a shareholder in HD Biosciences. |
| Shanghai Genomics | GNI (Tokyo, Japan), which collaborates with Shanghai Genomics via its integrated drug discovery platform, is a majority shareholder in Shanghai Genomics. |
| Shanghai Huaguan Biochip | Majority owned by Shanghai Biochip (Shanghai). |
| Shanghai United Cell Biotech | A subsidiary of United Laboratories (Mandaluyong City, Philippines). |
| Shenzhen Beike Biotechnologies | A joint venture between the Shenzhen government (Shenzhen, China), Peking University (Beijing) and the Hong Kong University of Science and Technology (Hong Kong). |
| SiBiono GeneTech | Benda Pharmaceutical (Hubei, China), through its 95% owned China-based subsidiary Hubei Tongji Benda Ebei Pharmaceutical (Hubei, China), owns a 57.6% majority share of SiBiono GeneTech. |
| SinoGenoMax | Affiliated with Chinese National Human Genome Centre of Beijing (Beijing). |
| Sinovac Biotech | Has formed a subsidiary, Sinovac Biotech Co., Ltd., also in Beijing, which is working on an inactivated HAV vaccine. Acquired Tangshan Yian Biological Engineering (Hebei, China) in 2004. |
| Tianjin SinoBiotech | Affiliated with Beijing Bioway-Fortune Research Center for Gene Drugs (Beijing). |
